Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
The J.P. Morgan Healthcare Conference runs this week from January 12 to 15. This healthcare conference is one of the largest and most important conferences for biotech companies all year.
January 15 is Day Four for the conference and a number of biotech companies will make presentations. Some will also have question and answer sessions after their presentations.
Here are some key times that select biotech companies are presenting on Thursday. The conference is in San Francisco; all times are in Pacific Standard Time.
8:00 AM: Sequenom, Inc. (NASDAQ: SQNM), Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
8:30 AM:TG Therapeutics Inc (NASDAQ: TGTX)
9:00 AM: Vivus, Inc. (NASDAQ: VVUS), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), Mimedx Group Inc (NASDAQ: MDXG), Antares Pharma Inc (NASDAQ: ATRS)
9:30 AM: Five Prime Therapeutics Inc (NASDAQ: FPRX)
10:00 AM: Stemline Therapeutics Inc (NASDAQ: STML), Dynavax Technologies Corporation (NASDAQ: DVAX)
10:30 AM: Pacific Biosciences of California (NASDAQ: PACB)
11:00 AM: PTC Therapeutics, Inc. (NASDAQ: PTCT), Amarin Corporation plc (ADR) (NASDAQ: AMRN), T2 Biosystems Inc (NASDAQ: TTOO)
11:30 AM: Protalix BioTherapeutics Inc. (NYSE: PLX)
12:00 PM: Kite Pharma Inc (NASDAQ: KITE), NxStage Medical, Inc. (NASDAQ: NXTM), AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), Sarepta Therapeutics Inc (NASDAQ: SRPT)
Related Link: JPMorgan Healthcare Conference: Here's What To Watch On Day 2
In the morning, investors will be watching Neurocrine after the company presented positive top-line data from its Phase 3 trial for elagolix.
Investors will also be tracking Sarepta after the company recently announced an update on its Phase 2 eteplirsen study. The stock traded down sharply on Monday, as the markets appeared to be disappointed with the data.
Kite Pharma, lastly, is another stock to keep an eye on. Kite is an immunotherapy company that went public in mid-2014. Since the IPO, the stock has tripled in price.
See more from Benzinga
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
